Eton Pharmaceuticals, Inc.ETON

NasdaqHealthcarePharmaceutical Preparations
Price (close)
$59.49
Market cap
$1.7B
P/E
134.0x
Revenue (TTM)
$105.6M
Net income
$12.7M
Dividend yield
—
1-year total return
195.4%
Net margin
12.0%
Revenue growth
81.5%
Debt / equity
0.60x

What Eton Pharmaceuticals, Inc. does.

Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. We currently have eight commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, KHINDIVI TM , GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. We have five additional product candidates in late-stage development: ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector.

INCRELEX® – This biologic product was approved by the FDA in August 2005 as a treatment for children who suffer from severe primary insulin-like growth factor 1 deficiency (SPIGFD). The product is approved in 40 territories, including the United States and the European Union. We acquired and launched the product in December 2024.

ALKINDI SPRINKLE® – This product was approved by the FDA in September 2020 as a replacement therapy for Adrenocortical Insufficiency (“AI”) in children under 17 years of age. The product is the first and only FDA-approved granule hydrocortisone formulation designed to help provide accurate dosing for newborns and children with AI. We acquired U.S. marketing rights to the product in March 2020 and launched ALKINDI SPRINKLE® in December 2020 with a sales force targeting pediatric endocrinologists. We believe there are approximately 10,000 children currently suffering from AI in the United States. ALKINDI SPRINKLE® is protected by three issued patents that extend to 2032, 2033, and 2034.

Revenue and profit, by fiscal year.

Fiscal year202020212022202320242025
Revenue$39,000$21.8M$21.3M$31.6M$39.0M$80.0M
Net income-$28.0M-$2.0M-$9.0M-$936,000-$3.8M-$4.6M
Free cash flow-$22.4M-$4.7M$4.8M$6.8M$943,000$10.2M

More on ETON.

Figures from Eton Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.